Pfizer

As 75 million boomers march steadily toward old age, a health care problem of monumental proportions awaits.

If you owned the bestselling prescription drug of all time and its patent was about to expire, how would you prepare for competition from generic drugs?

An experimental treatment for Alzheimer's disease has turned out to be a disappointment in the first finished late-stage study, manufacturer Pfizer said Monday. Called bapineuzumab, it's one of three Alzheimer's treatments currently in clinical trials that some have been calling our "last hope" for drugs that slow the progression of the disease.

A pneumonia vaccine previously recommended only for infants and young children, has now been approved for adults ages 50 and older, the Food and Drug Administration announced.